EP Vantage Issues 2012 Year in Review Report
LONDON AND BOSTON, March 27, 2013 /CNW/ - EP Vantage(R) [http://www.epvantage.com/default.aspx ], EvaluatePharma(R) [http://www.evaluatepharma.com ]'s award-winning editorial team, today released its "2012 Year in
Review [http://www.evaluatepharma.com/epvreview2012 ]" report. Despite numerous ups and downs, the sector exited on a
positive note, giving hope that 2013 might be the start of sustained
According to the report, Biotech stocks stormed ahead with the NASDAQ
Biotechnology Index up 32 percent; valuations not seen since the start
of the fiscal crisis. Significant fundraising also occurred in the
sector as quarterly data revealed that the final three months of 2012
saw $1.4 billion raised, marking the best quarter since Q4 2009. On the
downside, acquisitions and product deal activity remained stubbornly
low, especially in Europe.
The report also examines the year's record number of FDA approvals for
novel medicines and the impact this has had on R&D productivity. The
regulator approved 43 novel biologic or small-molecule agents in 2012,
up from 35 in 2011 and 26 in 2010. As for the patent cliff, branded
drugs with annual sales of $33.2 billion in 2011 lost patent protection
last year, leaving those revenues exposed to cheap generics.
To view the full "2012 Year in Review" report, go to http://www.evaluatepharma.com/EPVReview2012
"If there was one thing that defined 2012 it had to be the return of
investors' appetite for risk. We saw this both in the amount of money
raised during the year and also the valuations achieved by US biotechs.
While there is an argument that the US biotech sector is in danger of
becoming overvalued, I think that the green shoots seen in 2012 will
continue to grow in 2013. We have already seen some big ticket drug
launches in the form of Kadcyla and still have other potential
blockbusters like Tecfidera waiting in the wings," commented Lisa
Urquhart, Editor EP Vantage.
Examining the successes and failures that took place across the
industry, the "2012 Year in Review" includes answers to:
Who were the large, mid and small cap winners and losers in 2012?
Who raised the most amount of money in 2012?
How many total transactions occurred?
Where did the $20.9bn spent by big pharma go last year and how many
deals were struck?
Which acquisition was one of the biggest since 2000?
Has the quality of approved products improved over the last 10 years
and which products were the most successful in 2012?
Who fell off and who had the softest and hardest landings?
How much money was lost to generics in 2012?
About EP Vantage
Written by a team of award winning pharma journalists, EP Vantage [http://www.epvantage.com/default.aspx ] provides daily financial analysis of key industry catalysts
including: regulatory and patent decisions, marketing approvals,
licensing deals, and M&A - giving fresh angles and insight to both
current and future industry triggers.
Launched in 2007 by EvaluatePharma, EP Vantage's unique access to
EvaluatePharma data allows unrivaled, forward-looking, coverage of the
pharmaceutical and biotech industry.
About Evaluate Ltd.
Since 1996, EvaluatePharma [http://www.evaluatepharma.com ] has been the premier source for high quality life science sector
analysis, delivering exclusive consensus forecasts and trusted
commercial insight into biotech and pharmaceutical performance.
EvaluateMedTech sets a new standard in integrated analysis and
consensus forecasts of the global medical device and diagnostic
industry. EvaluateClinical Trials delivers unique intelligence to
efficiently and accurately analyze the global clinical trial landscape.
A team of over 85 dedicated healthcare analysts employ rigorous
methodologies to collate, organize and deliver the most-up-to-date
commercial performance data available. The Evaluate services enable the
life science community to make sound business decisions about value and
opportunity. For more information please visit http://www.EvaluatePharma.com.
SOURCE: Evaluate Ltd.
For further information:
EP Vantage and EvaluatePharma
Erik Clausen or Rachel Lear